Department of Thoracic Surgery, University of Toronto, Toronto, ON, Canada.
Eur J Cardiothorac Surg. 2013 Jun;43(6):1121-5. doi: 10.1093/ejcts/ezs623. Epub 2013 Jan 8.
The purpose of this study was to compare overall and disease-free survival after VATS and open lobectomy for clinical Stage I and II non-small-cell lung cancer (NSCLC).
A retrospective review of a prospective database of all patients undergoing VATS or open lobectomy for clinical Stage I or II NSCLC between 2002 and 2010 was performed. Postoperative outcomes, disease-free survival and overall survival were compared between the two groups after optimum 1:1 propensity matching for age, gender, tumour histology and pathological stage.
Over an 8-year period, 608 patients underwent lobectomy for NCSLC by VATS (n = 196, 32%) or open technique (n = 412, 68%). After matching, there were 190 patients in each group. Adenocarcinoma was found in 80% (open: 149, VATS: 152) and 55% of tumours were T1 (open: 108, VATS: 105). Pathological N1 disease was found in 21 and 19 patients in the open and VATS group, respectively. Disease-free 5-year survival was 69.1% for the open group vs 69.7% for VATS (P = 0.94). Cancer-specific 5-year survival was 82.9% for the open group vs 76.7% for VATS (P = 0.170). Five-year overall survival was 73% in the open group vs 64% in the VATS group (P = 0.17). Operative mortality and postoperative complications were not significantly different between groups.
Overall survival and disease-free survival are not significantly different when compared between VATS lobectomy and open lobectomy. VATS resection appears to provide an adequate oncological operation for patients with operable clinical Stage I and II NSCLC.
本研究旨在比较电视辅助胸腔镜手术(VATS)与开胸肺叶切除术治疗临床Ⅰ期和Ⅱ期非小细胞肺癌(NSCLC)的总生存率和无病生存率。
对 2002 年至 2010 年间所有接受 VATS 或开胸肺叶切除术治疗临床Ⅰ期或Ⅱ期 NSCLC 的患者前瞻性数据库进行回顾性分析。对两组患者的术后结果、无病生存率和总生存率进行比较,并采用最优 1:1 倾向评分匹配法对年龄、性别、肿瘤组织学和病理分期进行匹配。
在 8 年期间,608 例 NSCLC 患者接受了 VATS(n = 196,32%)或开胸手术(n = 412,68%)肺叶切除术。匹配后,每组各有 190 例患者。腺癌分别占开胸组(149 例)和 VATS 组(152 例)的 80%和 55%,T1 期肿瘤分别占 55%(开胸组 108 例,VATS 组 105 例)。开胸组和 VATS 组的病理 N1 期疾病分别为 21 例和 19 例。开胸组和 VATS 组的 5 年无病生存率分别为 69.1%和 69.7%(P = 0.94),癌症特异性 5 年生存率分别为 82.9%和 76.7%(P = 0.17)。开胸组和 VATS 组的 5 年总生存率分别为 73%和 64%(P = 0.17)。两组间手术死亡率和术后并发症无显著差异。
VATS 肺叶切除术与开胸肺叶切除术相比,总生存率和无病生存率无显著差异。VATS 切除术似乎为可手术治疗的临床Ⅰ期和Ⅱ期 NSCLC 患者提供了一种充分的肿瘤治疗方法。